¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ciba Foundation study group."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • follow-up study
    ÃßÀûÁ¶»ç
  • family study
    °¡Á·Á¶»ç
  • longitudinal study
    ÃßÀû¿¬±¸
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀÓ»óÀü½ÃÇè, ÀüÀӻ󿬱¸
  • pressure flow study
    ¾Ð·Â¿ä·ù°Ë»ç
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ecological study
    »ýÅ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸, ¾Õ¹æÇ⿬±¸, Àü¸Á¿¬±¸
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸, ȸ°í¿¬±¸
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
  • single blinding study
    ´Ü¼ø¸Í°Ë¹ý
  • urodynamic study
    ¿ä¿ªµ¿Çа˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • study design
    ¿¬±¸°èȹ
  • family study
    °¡Á·Á¶»ç
  • feasibility study
    °¡´É¼º¿¬±¸
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®Á¶»ç
  • intervening study
    °³ÀÔ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • microbiologic study
    ¹Ì»ý¹°Çа˻ç
  • migrant study
    ÀÌÁֹבּ¸
  • mixing study
    È¥ÇÕ°Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇа˻ç
  • neurophysiological study
    ½Å°æ»ý¸®ÇÐÀû°Ë»ç
  • nonconcurrent study
    ºñµ¿½ÃÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Coxsackie group A
    ÄÛ»èŰ A±º.
  • Coxsackie group B
    ÄÛ»èŰ B±º.
  • Diego blood group system
    µð¿¡°í Ç÷¾×Çü°è
  • GCR= group conformity rating
    Áý´ÜÇÕÄ¡ µî±ÞºÐ·ù.
  • Gag => group specifiic antigen/core
    ±×·ì<±º>ƯÀ̼º Ç׿ø/ÄÚ¾î
  • Kell blood group system
    ÄÌÇ÷¾×Çü±º
  • Kidd blood group system
    ۵åÇ÷¾×Çü±º
  • Lewis blood group system
    ·çÀ̽º Ç÷¾×Çü±º
  • Lutheran blood group system
    ·çÅͶõ Ç÷¾×Çü±º
  • P blood group system
    PÇ÷¾×Çü±º
  • Rh blood group
    RhÇ÷¾×Çü.
  • Rh blood group
    Rh Ç÷¾×Çü
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
  • nested case control study
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • retrospective study
    ÈÄÇâÀû¿¬±¸
  • single blind study
    ´ÜÀÏ<¼ø>¸Í°Ë¹ý.
  • time study
    ½Ã°£¿¬±¸(¡­æÚϼ).
  • tracer study
    ÃßÀûÀÚ¿¬±¸(õÚîæíºæÚϼ).
  • twin study
    ½Ö»ý¾Æ¿¬±¸(¡­æÚϼ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • carboxyl group
    Ä«¸£º¹½Ç±â(Ðñ)
  • complementation group
    »óº¸±º(ßÓÜÍÏØ)
  • critical group
    ÀӰ豺(×üÍ£ÏØ)
  • diazo group
    µð¾ÆÁ¶ ±â(Ðñ)
  • diazonium group
    µð¾ÆÁ¶´½ ±â(Ðñ)
  • earthy group
    Å伺±â(÷ÏàõÐñ)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fatty acyl group
    Áö¹æ(ò·Û¸) ¾Æ½Ç±â(Ðñ)
  • fidelity group
    Á¤È®µµ ±â(ïáü¬ÓøÐñ)
  • formimino group
    Æ÷¸§À̹̳ë±â(Ðñ)
  • formyl group
    Æ÷¸£¹Ð±â(Ðñ)
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ)
  • functional group isomer
    ÀÛ¿ë±â(íÂéÄÐñ) À̼ºÃ¼(ì¶àõô÷)
  • glucosyl group
    ±Û·çÄڽDZâ(Ðñ)
  • glycoaldehyde group
    ±Û¶óÀÌÄھ˵¥ÇÏÀ̵å±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NAF nafcillin; National Amputation Foundation; National Ataxia Foundation; net acid flux
NOF National Osteopathic Foundation; National Osteoporosis Foundation
EF study Ejection-Fraction study
KAP study Knowledge, Attitude & Practice study
AASK African American Study of Kidney Diseases and Hypertension Pilot Study
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SEOPF South Eastern Organ Procurement Foundation
Study 1 study
Study 2 study
Study A study
Study B study
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Lutheran blood group
    ·çÅ×¶õ½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ ÀÏÁ¾. ¿ì¿­ÀÌ ¾ø´Â ÇÑ ½ÖÀÇ ´ë¸³ À¯ÀüÀÚ Lu, Lu¿¡ ÀÇÇØ¼­ Áö¹èµÇ°í, ÀÌ À¯ÀüÀÚÀÇ Á¶ÇÕ¿¡ µû¶ó¼­ »ç¶÷ÀÇ Ç÷±¸´Â Lu
  • methyl green-pyronin of nucleolus

    methyl group

    ¸ÞÄ¥±â
  • myelinated group
    À¯¼öÃʱº
  • open group
    °ø°³ Áý´Ü
  • posterior group nuclei
    ÈĺΠÇÙ
  • posterior nuclear group
    ÈÄÇÙ Áý´Ü
  • prosthetic group
    ¹èÇÕ±º
  • Q : Àü±â·®ÀÇ coulombÀÇ ±âÈ£.

    Q blood group system

    Å¥½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. µÅÁö Ç÷ûÀÇ ¾î¶² °Í¿¡ Á¸ÀçÇÏ´Â Ç× Q ÀÀÁý¼Ò¸¦ °¡ÇßÀ» ¶§ ÀÀÁýÇϴ°¡ ÇÏÁö ¾Ê´Â°¡¿¡ µû¶ó Ç÷¾×À» ºÐ·ùÇÏ´Â °ÍÀÌ´Ù. Ç× QÀÀÁý¼Ò´Â P½Ä Ç÷¾×ÇüÀÇ Ç× P ÀÀÁý¼Ò¿Í µ¿ÀÏÇÑ °ÍÀ̶ó´Â Çм³µµ ÀÖ´Ù.
  • Rh blood group
    Rh Ç÷¾×Çü, ¾Æ¸£ ¿¡ÀÌÄ¡½Ä Ç÷¾×Çü
    1940³â ¹Ì±¹ÀÇ K. ¶õÆ®½´Å¸ÀÌ³Ê µî¿¡ ÀÇÇÏ¿© ¹ß°ßµÈ ÀÓ»óÀûÀ¸·Î ¾ÆÁÖ Áß¿äÇÑ Ç÷¾×Çü. Rh¶ó´Â °ÍÀº, óÀ½¿¡ À̰ÍÀ» °ËÃâÇϴµ¥ ÇÊ¿äÇÑ Ç×Ç÷ûÀ» ¾ò±â À§ÇÏ¿© »ç¿ëÇÑ ¸é¿ª µ¿¹°ÀÎ ºÓÀºÅпø¼þÀÌ
  • S-blood group
    ¿¡½º½Ä Ç÷¾×Çü
    ABO½Ä Ç÷¾×Çü°ú °ü°è ÀÖ´Â Ç÷¾×Çü. Ç÷¾×ÀÇ ºÐºñÇü, ºñºÐºñÇüÀÇ ºÐ·ù¶ó°í Çϸç, 1932³â µ¶ÀÏÀÇ F. ½ÃÇÁ°¡ ¹ß°ßÇÏ¿´´Ù. ABO½Ä Ç÷¾×Çü¿¡ ¼ÓÇÏ´Â Ç׿ø ¹°Áú
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
  • air study
    °ø±â °Ë»ç, °ø±â ÁÖÀÔ °Ë»ç, °ø±â °Ë»ç¹ý, °ø±â ÁÖÀÔ °Ë»ç¹ý
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • case control study
    ȯÀÚ ´ëÁ¶ ¿¬±¸
  • case study
    Áõ·Ê ¿¬±¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
multigeneration study Toxicity test in which at least 3 generations of the test organisms are exposed to the substance being assessed. Exposure is usually continuous.
Any medical study which follows a family of people through several generations.
(09 Oct 1997)
crossover study <statistics> A study that compares two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. Usually refers to a study in which the subject is switched from the experimental to the control procedure (or vice versa).
In the case of two treatments, a and b, half the subjects are randomly allocated to receive these in the order a, b and half to receive them in the order b, a.
A criticism of this design is that effects of the first treatment may carry over into the period when the second is given.
With this type of study, every patient serves as his or her own control.
(21 Jun 2000)
cross-sectional study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
preclinical study A study to test a drug, procedure or other medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
prospective study <epidemiology> A study in which people are initially enrolled and then followed up at subsequent times.
(05 Dec 1998)
study 1. To apply the mind to; to read and examine for the purpose of learning and understanding; as, to study law or theology; to study languages.
2. To consider attentively; to examine closely; as, to study the work of nature. "Study thyself; what rank or what degree The wise Creator has ordained for thee." (Dryden)
3. To form or arrange by previous thought; to con over, as in committing to memory; as, to study a speech.
4. To make an object of study; to aim at sedulously; to devote one's thoughts to; as, to study the welfare of others; to study variety in composition. "For their heart studieth destruction." (Prov. Xxiv. 2)
Origin: OE. Studie, L. Studium, akin to studere to study; possibly akin to Gr. Haste, zeal, to hasten; cf. OF. Estudie, estude, F. Etude. Cf. Etude, Student, Studio, Study, v. I.
1. A setting of the mind or thoughts upon a subject; hence, application of mind to books, arts, or science, or to any subject, for the purpose of acquiring knowledge. "Hammond . . . Spent thirteen hours of the day in study." (Bp. Fell) "Study gives strength to the mind; conversation, grace." (Sir W. Temple)
2. Mental occupation; absorbed or thoughtful attention; meditation; contemplation. "Just men they seemed, and all their study bent To worship God aright, and know his works." (Milton)
3. Any particular branch of learning that is studied; any object of attentive consideration. "The Holy Scriptures, especially the new Testament, are her daily study." (Law) "The proper study of mankind is man." (Pope)
4. A building or apartment devoted to study or to literary work. "His cheery little study."
5. A representation or rendering of any object or scene intended, not for exhibition as an original work of art, but for the information, instruction, or assistance of the maker; as, a study of heads or of hands for a figure picture.
6. A piece for special practice. See Etude.
Source: Websters Dictionary
(01 Mar 1998)
study, crossover A type of clinical trial in which the study subjects receive each treatment in a random order. In this type of study, every patient serves as his or her own control.
(12 Dec 1998)
study, cross-sectional A study done at one time, not over the course of time. A cross-sectional study a disease such as aids might be designed to learn its prevalence and distribution within the population at one point in time. Also known as a synchronic study.
(12 Dec 1998)
study, diachronic See: Study, longitudinal.
(12 Dec 1998)
study, longitudinal A study done over the passage of time. For example, a longitudinal study of children with down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a diachronic study. The opposite of a cross-sectional (synchronic) study.
(12 Dec 1998)
study, preclinical A study to test a drug, procedure or medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
study, synchronic See: Study, cross-sectional.
(12 Dec 1998)
synchronic study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
diachronic study A study done over the course of time. For example, a longitudinal study of children with Down syndrome (trisomy 21) might involve the study of 100 children with this condition from birth to 10 years of age. Also called a longitudinal study. The opposite of a synchronic (cross-sectional) study.
(12 Dec 1998)
double-blind study A study in which neither the experimenter nor any other assessor of the results, including patients, know which group is subject to which procedure, thus helping assure that the biases or expectations of either will not influence the results.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • field study
    =FIELDWORK
  • home study
    (Åë½Å ±³À°¿¡¼­ÀÇ)ÀÚÅà ÇнÀ;(¹Ì)(¾çºÎ¸ð·Î¼­ÀÇ ÀûºÎ¸¦ ¾Ë¾Æº¸´Â)°¡Á¤Á¶»ç
  • home study
    Åë½Å±³À°
  • nature study
    ÀÚ¿¬°øºÎ(²É »õ ±¤¼® ³¯¾¾µîÀÇ °üÂû,±¹¹ÎÇб³ÀÇ Çаú ''
  • study
    ½ÀÀÛ;½ÃÀÛ;¼­Àç;¿¬±¸½Ç;¾Ö¾¸
  • study
    ÇÏ´Ù;¾Ö¾²´Ù;(¹Ì)¼÷°íÇÏ´Ù
  • study
    ÇÏ´Ù;(´ë»çµîÀ»)¾Ï±âÇÏ´Ù
  • age-group
    ¿¬·É Áý´Ü
  • group
    Áý´Ü,¶¼¸¦ Áþ´Ù,ºÐ·ùÇÏ´Ù
  • Group of 77
    77°³±¹ ±×·ì(UNÀÇ ¹«¿ª°³¹ß ȸÀÇ(UNCTAD)ÀÇ È¸¿øÀÎ ¹ßÀü µµ»ó±¹ ±×·ì)
  • Group of Seven
    G;7 ¼±Áø 7°³±¹ ±×·ì
  • blood group
    Ç÷¾×Çü Á¤
  • code group
    ºÎÈ£±º
  • continuous group
    ¿¬¼Ó±º
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á